Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Mr. John  Felitti J.D., LLM

Vice President, General Counsel & Corporate Secretary

Mr. James  Wentworth M.B.A., Ph.D.

Vice President & Chief Business Officer

Ms. Gaelle  Stadtler

Vice President & Director of Human Resources

Ms. Christelle  Schwoerer

Chief Human Resources Officer

Ms. Lucie  Larguier

Chief Financial Officer

Dr. Maud  Brandely-Talbot M.D., Ph.D.

Vice President of Medical Affairs & Chief Medical Officer

Kaidre  Bendjama

Project Leader of Personalized Cancer Vaccines

Dr. Alessandro  Riva M.D.

Chief Executive Officer & Chairman of the Board

Ms. Elisabetta  Castelli Ph.D.

Director of Investor Relations

Dr. Eric  Quemeneur Ph.D., Pharm.D.

Executive Vice President & Chief Scientific Officer

Име	Пазарна капитализация
Affimed N.V.	0M
Halozyme Therapeutics, Inc.	0M
Homology Medicines, Inc.	0M
Walgreens Boots Alliance Inc	0M
Nektar Therapeutics	0M
Camurus AB (publ)	0M
Relief Therapeutics Holding AG	0M
Blueprint Medicines Corporation	0M
Pa Shun International Holdings Limited	0M
Invitae Corporation	0M

Transgene SA

Transgene SA Списък на конкурентите

Основни конкуренти